Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis

Overview of attention for article published in Arthritis Research & Therapy, April 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 3 news outlets

twitter: 7 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 10 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 14,720 followers.

RT @EMEUNET: In our Paediatric Rheumatology October #WhatIsNew contribution, @KearsleyFleet "In this large real-world analysis, those who s…

10 Oct 2021

Reply Repost Favourite

RT @EMEUNET: In our Paediatric Rheumatology October #WhatIsNew contribution, @KearsleyFleet "In this large real-world analysis, those who s…

08 Oct 2021

Reply Repost Favourite

In our Paediatric Rheumatology October #WhatIsNew contribution, @KearsleyFleet "In this large real-world analysis, those who started etanercept therapy sooner (after JIA onset) were more likely to stop therapy after achieving inactive disease" https://t.c

08 Oct 2021

Reply Repost Favourite

"Window of Opportunity" applies for pediatric rheum patients, too!

13 May 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.